Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis

Experimental and Molecular Pathology

Volumn 97, Issue 2, 2014, Pages 298-304

  Maroof, Hamidreza ^a   Salajegheh, Ali ^a   Smith, Robert Anthony ^a   Lam, Alfred King Yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Cancer; MiRNA 34

Indexed keywords

MICRORNA; MICRORNA 126; MICRORNA 130A; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 17 92; MICRORNA 200C; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 210; MICRORNA 217; MICRORNA 221; MICRORNA 222; MICRORNA 27B; MICRORNA 296; MICRORNA 31; MICRORNA 320; MICRORNA 34; MICRORNA 34A; MICRORNA 34B; MICRORNA 378; MICRORNA 424; MICRORNA 9; UNCLASSIFIED DRUG;

CANCER CELL LINE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; TUMOR MICROENVIRONMENT;

ANGIOGENESIS; CANCER; MIRNA-34;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84910137929     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.08.002     Document Type: Review

References (152)

1. Aghajanian C., Goff B., Nycum L.R., Wang Y., Husain A., Blank S. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol. Oncol. 2014, 133:105-110.
2. Alaiti M.A., Ishikawa M., Masuda H., Simon D.I., Jain M.K., Asahara T., et al. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J. Cell. Mol. Med. 2012, 16:2413-2421.
3. Ambros V. MicroRNAs and developmental timing. Curr. Opin. Genet. Dev. 2011, 21:511-517.
4. Arany Z., Foo S.-Y., Ma Y., Ruas J.L., Bommi-Reddy A., Girnun G., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1&agr. Nature 2008, 451:1008-1012.
5. Arjaans M., Munnink T.H.O., Oosting S.F., van Scheltinga A.G.T., Gietema J.A., Garbacik E.T., et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013, 73:3347-3355.
6. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
7. Bagri A., Kouros-Mehr H., Leong K.G., Plowman G.D. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol. Med. 2010, 16:122-132.
8. Bao M.-H., Feng X., Zhang Y.-W., Lou X.-Y., Cheng Y., Zhou H.-H. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. Int. J. Mol. Sci. 2013, 14:23086-23102.
9. Bartel D.P., Chen C.-Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 2004, 5:396-400.
10. Benetti R., Gonzalo S., Jaco I., Muñoz P., Gonzalez S., Schoeftner S., et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol. 2008, 15:268-279.
11. Bhaumik D., Scott G.K., Schokrpur S., Patil C.K., Orjalo A.V., Rodier F., et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging 2009, 1:402.
12. Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.-F., Dunning M.J., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8:R214.
13. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
14. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
15. Breier G. Angiogenesis in embryonic development-a review. Placenta 2000, 21:S11-S15.
16. Brekken R.A., Overholser J.P., Stastny V.A., Waltenberger J., Minna J.D., Thorpe P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000, 60:5117-5124.
17. Brooks C.L., Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nat. Rev. Cancer 2009, 9:123-128.
18. Cai Y., Yu X., Hu S., Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinforma. 2009, 7:147-154.
19. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 2002, 99:15524-15529.
20. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
21. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
22. Catto J.W., Alcaraz A., Bjartell A.S., De Vere White R., Evans C.P., Fussel S., et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 2011, 59:671-681.
23. Cha Y.H., Kim N.H., Park C., Lee I., Kim H.S., Yook J.I. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 2012, 11:1273-1281.
24. Chang T.-C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
25. Chen F., Hu S.J. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J. Biochem. Mol. Toxicol. 2012, 26:79-86.
26. Chen J.J., Lin Y.-C., Yao P.-L., Yuan A., Chen H.-Y., Shun C.-T., et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005, 23:953-964.
27. Chen L.T., Xu S.D., Xu H., Zhang J.F., Ning J.F., Wang S.F. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med. Oncol. 2012, 29:1673-1680.
28. Chim C., Wong K., Qi Y., Loong F., Lam W., Wong L., et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31:745-750.
29. Chiosea S., Jelezcova E., Chandran U., Luo J., Mantha G., Sobol R.W., et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67:2345-2350.
30. Cho W. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42:1273-1281.
31. Choi Y.J., Lin C.-P., Ho J.J., He X., Okada N., Bu P., et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat. Cell Biol. 2011, 13:1353-1360.
32. Christoffersen N.R., Shalgi R., Frankel L., Leucci E., Lees M., Klausen M., et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010, 17:236-245.
33. Concepcion C.P., Han Y.-C., Mu P., Bonetti C., Yao E., D'andrea A., et al. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 2012, 8:e1002797.
34. Corney D.C., Hwang C.-I., Matoso A., Vogt M., Flesken-Nikitin A., Godwin A.K., et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 2010, 16:1119-1128.
35. de Antonellis P., Medaglia C., Cusanelli E., Andolfo I., Liguori L., De Vita G., et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 2011, 6:e24584.
36. Doebele C., Bonauer A., Fischer A., Scholz A., Reiss Y., Urbich C., et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010, 115:4944-4950.
37. Dorsett Y., McBride K.M., Jankovic M., Gazumyan A., Thai T.-H., Robbiani D.F., et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated myc-Igh translocation. Immunity 2008, 28:630-638.
38. Ebrahimi F., Gopalan V., Smith R.A., Lam A.K. miR-126 in human cancers: clinical roles and current perspectives. Exp. Mol. Pathol. 2014, 96:98-107.
39. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
40. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
41. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
42. Ferrara N., Hillan K.J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
43. Flamme I., Frölich T., Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 1997, 173:206-210.
44. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
45. Ge Y., Chen J. MicroRNAs in skeletal myogenesis. Cell Cycle 2011, 10:441-448.
46. Ghosh G., Subramanian I.V., Adhikari N., Zhang X., Joshi H.P., Basi D., et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J. Clin. Invest. 2010, 120:4141-4154.
47. Gopalan V., Pillai S., Ebrahimi F., Salajegheh A., Lam T.C., Le T.K., Langsford N., Ho Y.H., Smith R.A., Lam A.K. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. Mol. Carcinog. 2014, 53(Suppl. 1):E36-E44.
48. Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010, 141:129-141.
49. Harhaj N.S., Felinski E.A., Wolpert E.B., Sundstrom J.M., Gardner T.W., Antonetti D.A. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 2006, 47:5106-5115.
50. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65:9628-9632.
51. Hellstrom M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
52. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
53. Houbaviy H.B., Murray M.F., Sharp P.A. Embryonic stem cell-specific microRNAs. Dev. Cell 2003, 5:351-358.
54. Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1721-1726.
55. Hu Q., Jiang Q., Jin X., Shen J., Wang K., Li Y., et al. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 2013, 34:2265-2276.
56. Huang Y., Shen X.J., Zou Q., Wang S.P., Tang S.M., Zhang G.Z. Biological functions of microRNAs: a review. J. Physiol. Biochem. 2011, 67:129-139.
57. Inui M., Martello G., Piccolo S. MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 2010, 11:252-263.
58. Irani S., Salajegheh A., Gopalan V., Smith R.A., Lam A.K. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics. Ann. Diagn. Pathol. 2014, 18:43-48.
59. Irani S., Salajegheh A., Smith R.A., Lam A.K. A review of the profile of endothelin axis in cancer and its management. Crit. Rev. Oncol. Hematol. 2014, 89:314-321.
60. Ito T., Yagi S., Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem. Biophys. Res. Commun. 2010, 398:735-740.
61. Javeri A., Ghaffarpour M., Taha M.F., Houshmand M. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med. Oncol. 2013, 30:1-10.
62. Ji Q., Hao X., Meng Y., Zhang M., DeSano J., Fan D., et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.
63. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
64. Karube Y., Tanaka H., Osada H., Tomida S., Tatematsu Y., Yanagisawa K., et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96:111-115.
65. Kasinski A.L., Slack F.J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
66. Kato M., Paranjape T., Ullrich R., Nallur S., Gillespie E., Keane K., et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009, 28:2419-2424.
67. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
68. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
69. Kong D., Heath E., Chen W., Cher M., Powell I., Heilbrun L., et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am. J. Transl. Res. 2012, 4:14.
70. Kong W., He L., Richards E., Challa S., Xu C., Permuth-Wey J., et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014, 33:679-689.
71. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28:453-459.
72. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.-W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
73. Koufaris C., Wright J., Currie R.A., Gooderham N.J. Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic hepatocarcinogens. Toxicol. Sci. 2012, 128:532-543.
74. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
75. Kubo T., Toyooka S., Tsukuda K., Sakaguchi M., Fukazawa T., Soh J., et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin. Cancer Res. 2011, 17:4965-4974.
76. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. 2008, 105:3903-3908.
77. Kumar B., Yadav A., Lang J., Teknos T.N., Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 2012, 7:e37601.
78. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
79. Lal A., Thomas M.P., Altschuler G., Navarro F., O'Day E., Li X.L., et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011, 7:e1002363.
80. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
81. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
82. Lehmann U., Hasemeier B., Christgen M., Müller M., Römermann D., Länger F., et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 2008, 214:17-24.
83. Li N., Fu H., Tie Y., Hu Z., Kong W., Wu Y., et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009, 275:44-53.
84. Li Q., Bian S., Hong J., Kawase-Koga Y., Zhu E., Zheng Y., et al. Timing specific requirement of microRNA function is essential for embryonic and postnatal hippocampal development. PLoS One 2011, 6:e26000.
85. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
86. Liu L.-Z., Li C., Chen Q., Jing Y., Carpenter R., Jiang Y., et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One 2011, 6:e19139.
87. Liu N., Landreh M., Cao K., Abe M., Hendriks G.-J., Kennerdell J.R., et al. The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature 2012, 482:519-523.
88. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
89. Loughna S., Sato T.N. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol. 2001, 20:319-325.
90. Ma J., Chen C.-S., Blute T., Waxman D.J. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011, 71:2675-2685.
91. Manley P.W., Bold G., Brüggen J., Fendrich G., Furet P., Mestan J., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta Protein Proteomics 2004, 1697:17-27.
92. Mazar J., Khaitan D., DeBlasio D., Zhong C., Govindarajan S.S., Kopanathi S., et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One 2011, 6:e24922.
93. Miles K. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur. J. Radiol. 1999, 30:198-205.
94. Mudduluru G., Ceppi P., Kumarswamy R., Scagliotti G., Papotti M., Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011, 30:2888-2899.
95. Muralidhar B., Goldstein L., Ng G., Winder D., Palmer R., Gooding E., et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 2007, 212:368-377.
96. Nakashima T., Jinnin M., Etoh T., Fukushima S., Masuguchi S., Maruo K., et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One 2010, 5:e14334.
97. Nalls D., Tang S.-N., Rodova M., Srivastava R.K., Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011, 6:e24099.
98. Nicoli S., Knyphausen C.-P., Zhu L.J., Lakshmanan A., Lawson N.D. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev. Cell 2012, 22:418-429.
99. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cell Mol. Dis. 2007, 39:212-220.
100. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365:2484-2496.
101. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
102. Rebustini I.T., Hayashi T., Reynolds A.D., Dillard M.L., Carpenter E.M., Hoffman M.P. miR-200c regulates FGFR-dependent epithelial proliferation via Vldlr during submandibular gland branching morphogenesis. Development 2012, 139:191-202.
103. Reis S.T., Leite K.R.M., Piovesan L.F., Pontes-Junior J., Viana N.I., Abe D.K., et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol. 2012, 12:18.
104. Rinaldi A., Poretti G., Kwee I., Zucca E., Catapano C.V., Tibiletti M.G., et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk. Lymphoma 2007, 48:410-412.
105. Roy S., Levi E., Majumdar A., Sarkar F.H. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J. Hematol. Oncol. 2012, 5:58.
106. Salajegheh A., Smith R.A., Kasem K., Gopalan V., Nassiri M.R., William R., Lam A.K. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur. J. Surg. Oncol. 2011, 37:93-99.
107. Salajegheh A., Pakneshan S., Rahman A., Dolan-Evans E., Zhang S., Kwong E., Gopalan V., Lo C.Y., Smith R.A., Lam A.K. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. Hum. Pathol. 2013, 44:2204-2212.
108. Savi F., Forno I., Faversani A., Luciani A., Caldiera S., Gatti S., et al. miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. Clin. Sci. 2014, 127:233-242.
109. Sayed D., Abdellatif M. MicroRNAs in development and disease. Physiol. Rev. 2011, 91:827-887.
110. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. 2009, 106:1814-1819.
111. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
112. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8:S62-S67.
113. Sevignani C., Calin G.A., Nnadi S.C., Shimizu M., Davuluri R.V., Hyslop T., et al. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc. Natl. Acad. Sci. 2007, 104:8017-8022.
114. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012, 320:130-137.
115. Siemens H., Jackstadt R., Hunten S., Kaller M., Menssen A., Gotz U., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10:4256-4271.
116. Siemens H., Neumann J., Jackstadt R., Mansmann U., Horst D., Kirchner T., et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin. Cancer Res. 2013, 19:710-720.
117. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 2010, 38:323-332.
118. Sitohy B., Nagy J.A., Dvorak H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012, 72:1909-1914.
119. Suárez Y., Fernández-Hernando C., Yu J., Gerber S.A., Harrison K.D., Pober J.S., et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4082-4087.
120. Sun C.Y., She X.M., Qin Y., Chu Z.B., Chen L., Ai L.S., et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013, 34:426-435.
121. Szulwach K.E., Li X., Smrt R.D., Li Y., Luo Y., Lin L., et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 2010, 189:127-141.
122. Tagawa H., Karube K., Tsuzuki S., Ohshima K., Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci. 2007, 98:1482-1490.
123. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. 2007, 104:15472-15477.
124. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y., et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008, 68:4123-4132.
125. Tsao M.-S., Sakurada A., Cutz J.-C., Zhu C.-Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353:133-144.
126. Vaira V., Faversani A., Dohi T., Montorsi M., Augello C., Gatti S., et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012, 31:27-38.
127. van Kouwenhove M., Kedde M., Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat. Rev. Cancer 2011, 11:644-656.
128. Vogt M., Munding J., Grüner M., Liffers S.-T., Verdoodt B., Hauk J., et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011, 458:313-322.
129. Volpe M., Nielsen H., Mujahid S. Opposing roles of Mir-221 and Mir-130a in neovascularization during lung branching morphogenesis. Am. J. Respir. Crit. Care Med. 2012, 185:A4978.
130. Wan G., Mathur R., Hu X., Zhang X., Lu X. miRNA response to DNA damage. Trends Biochem. Sci. 2011, 36:478-484.
131. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
132. Wang X., Huang W., Liu G., Cai W., Millard R.W., Wang Y., et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J. Mol. Cell. Cardiol. 2014, 74:139-150.
133. Watahiki A., Wang Y., Morris J., Dennis K., O'Dwyer H.M., Gleave M., et al. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011, 6:e24950.
134. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
135. Weekes J., Ho Y.H., Sebesan S., Ong K., Lam A.K. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int. J. Color. Dis. 2010, 25:907.
136. Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-Oncology 2011, 13:165-175.
137. Welch S.A., Moore M.J. Erlotinib: Success of a Molecularly Targeted Agent for the Treatment of Advanced Pancreatic Cancer 2007.
138. Welti J., Loges S., Dimmeler S., Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 2013, 123:3190-3200.
139. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
140. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11:228-234.
141. Wu Y.-Y., Chen Y.-L., Jao Y.-C., Hsieh I.-S., Chang K.-C., Hong T.-M. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis 2014, 17:247-260.
142. Yamakuchi M., Lowenstein C.J. MiR-34, SIRT1 and p53. Cell Cycle 2009, 8:712-715.
143. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. 2008, 105:13421-13426.
144. Yan L.X., Wu Q.N., Zhang Y., Li Y.Y., Liao D.Z., Hou J.H., et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011, 13:R2.
145. Yang W.J., Yang D.D., Na S., Sandusky G.E., Zhang Q., Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J. Biol. Chem. 2005, 280:9330-9335.
146. Yu X.M., Lo C.Y., Lam A.K., Lang B.H., Leung P., Luk J.M. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008, 144:934-940.
147. Yu X.M., Lo C.Y., Lam A.K., Leung P., Luk J.M. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 2008, 247:483-489.
148. Yu F., Jiao Y., Zhu Y., Wang Y., Zhu J., Cui X., et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J. Biol. Chem. 2012, 287:465-473.
149. Zhang Q., Kandic I., Kutryk M.J. Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem. Biophys. Res. Commun. 2011, 405:42-46.
150. Zhang S., Liu L., Wang R., Tuo H., Guo Y., Yi L., et al. MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. PLoS One 2013, 8:e83620.
151. Zhao T., Li J., Chen A.F. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E110.
152. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Guan Y., et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31:3513-3523.